Effect of intravenous tiludronate disodium administration on the radiographic progression of osteoarthritis of the fetlock joint in Standardbred racehorses.

The article examines the effect of Tiludronate disodium, a medication used in treating osteoarthritis, on the radiographic progression of osteoarthritis in the fetlock joint of Standardbred racehorses.

Objective of the Study

• The research primarily focused on comparing the effects of Tiludronate disodium and three other treatments (triamcinolone acetonide and hyaluronan, polysulfated glycosaminoglycan, or interleukin-1 receptor antagonist protein administered via intra-articular route) on clinical, radiographic findings, and biomarkers of disease progression in horses with osteoarthritis of the fetlock joint.

Methodology

• The study examined 100 Standardbred racehorses who had sustained a spontaneous traumatic injury of the fetlock joint.
• The horses were systematically grouped based on the treatment they received: Tiludronate disodium administered as an intravenous injection or others received intra-articular injections of triamcinolone acetonide and hyaluronan, polysulfated glycosaminoglycan, or interleukin-1 receptor antagonist protein.
• Data were collected on clinical, radiographic, and ultrasonographic findings, and the results for both serum and synovial samples were obtained before and 6 months after treatment. These measurements included biomarkers such as TNF-α, CTX-I, CTX-II, IL-1β, and Prostaglandin E.

Findings

• All the treatments resulted in substantial improvement in the horses’ lameness and joint flexion test score at six months, suggesting a positive response to the treatment strategies.
• In horses treated with triamcinolone acetonide and hyaluronan, synovial fluid IL-1β, prostaglandin E, and CTX-II concentrations decreased after treatment. This suggests that this treatment method may hinder hyaline cartilage degeneration and the inflammatory process, which are found in osteoarthritis.
• Only the horses treated with Tiludronate displayed a decrease in radiographic scores and serum CTX-I concentration after treatment, suggesting its significant effect on bone metabolism.
• However, Tiludronate treatment also led to an increase in serum and synovial fluid concentrations of CTX-II, a biomarker indicating cartilage damage, suggesting potential cartilage damage as a consequence of the treatment.

Conclusion

• According to the results, Tiludronate appears to hinder the radiographic progression of osteoarthritis in high-motion joints in racehorses at six months after treatment by inhibiting bone remodeling.
• However, its effect was also linked with a possible increase in progressive cartilage damage, provoking further research on the long-term effect of this medication.